ClinicalTrials.gg
CompletedNCT00034853Updated Nov 1, 2013

Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)

A Phase 3 interventional study of meloxicam oral suspension and naproxen oral suspension in Arthritis, Juvenile Rheumatoid, sponsored by Boehringer Ingelheim. Completed at 37 sites in 4 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2013-11-01.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 109 studies in Arthritis, Juvenile with a site in United States — 20 open to participants now, 23 under way, 5 of them phase 3. Arthritis, Juvenile · United States.

Planned enrollment
18th of 83
180 · median 55
Started
2000
with 2 others
Phase 3
30 of 109
5 open now
Registered
8th of 109
by date

Among the 109 studies in Arthritis, Juvenile with a site in United States, this one is the 18th largest by planned enrollment of the 83 interventional ones that give a count, is one of 3 that started in 2000, is one of 30 in phase 3, and was the 8th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

20 of the 109 studies in Arthritis, Juvenile with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Arthritis, Juvenile with a site in United States, or all of them as a file.
02

Study summary

To obtain safety, efficacy, pharmacokinetic and dosing information for meloxicam oral suspension in children with Juvenile Rheumatoid Arthritis (JRA)

03

Conditions studied

  • Arthritis, Juvenile Rheumatoid

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of juvenile idiopathic arthritis (JIA) by International League of Associations for Rheumatology (ILAR) criteria; pauciarthritic, extended pauciarthritic, or polyarthritic current course of disease;
  • active arthritis of at least 2 joints
  • at least 2 other abnormal variables of the 5 remaining core set parameters
  • require nonsteroidal anti-inflammatory drugs (NSAIDs)
  • children aged 2-17 years

Exclusion criteria

Exclusion Criteria:

  • systemic course of juvenile idiopathic arthritis
  • all rheumatic conditions not included in inclusion criteria; any clinical finding or abnormal lab (not due to JIA) that could interfere with conduct of clinical trial
  • weight of 9 kg or less
  • pregnancy or breast feeding
  • females of who are sexually active and not using adequate for at least 3 mos prior to and for duration of study
  • history of bleeding disorder, gastrointestinal bleeding, or cerebrovascular bleeding
  • peptic ulcer past 6 months
  • more than 1 disease modifying anti-rheumatic drug (DMARD) or change in DMARD during 3 months prior
  • change during 1 month prior
  • systemic corticosteroids greater than 10 mg/d, hydroxychloroquine greater than 10/mg/d, cyclosporine greater than 5 mg/kg/d., methotrexate greater than 15 mg/m2/wk, cytotoxic agents, gold, D-penicilamine, sulfasalazine, glucosamine, and products
  • etanercept during 1 month prior; infliximab during 2 months prior; intra-articular corticosteroids during 1 month prior
  • patients requiring concomitant other NSAID including topical (excluding ophthalmic)
  • requirement for use of other NSAIDs, anticoagulants, phenothiazine, lithium, or ACTH
  • insufficient effect or intolerability to naproxen or meloxicam
  • known or suspected to trial meds or their
  • requirement of chronic H2 antagonist
  • history of asthma, nasal polyps, angioneurotic edema, or urticaria with aspirin or NSAIDs
  • planned surgical procedures during study
  • investigational drug exposure during this trial or within 30 days (or 6 half lives, whichever greater) prior
  • previous participation in this trial
  • patients with known drug or alcohol abuse
  • patient, parent or legal representative unable to understand and to comply with protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
180 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Responder rate by core set of outcome criteria (Juvenile Rheumatoid Arthritis Pediatric 30): global assessment disease activity; functional disability, number joints arthritis, limited motion; erythrocyte sedimentation rate;

    Time frame: week 12

Secondary outcomes

  1. Individual core set outcome criteria; final global assessment of efficacy; tolerability; AE incidence and intensity; withdrawals; acetaminophen consumption; safety labs: physical examination; hospitalization for gastrointestinal (GI) SAE, GI AE

    Time frame: weeks 4, 8, 12, 18, and 24

07

Study locations

37 sites
  • 107.235.23 Arkansas Children's Hospital
    Little Rock, Arkansas, United States
  • 107.235.17 Valley Children's Hospital
    Madera, California, United States
  • 107.235.37
    San Diego, California, United States
  • 107.235.4 Boehringer Ingelheim Investigational Site
    Denver, Colorado, United States
  • 107.235.12 Boehringer Ingelheim Investigational Site
    Hartford, Connecticut, United States
  • 107.235.13 Alfred I. DuPont Hospital for Children
    Wilmington, Delaware, United States
  • 107.235.36 Arthritis Associates Clinical Research of South Florida
    Del Ray Beach, Florida, United States
  • 107.235.21 Miami Children's Hospital
    Miami, Florida, United States
  • 107.235.38 Clinical Research Dept #7006
    St. Petersberg, Florida, United States
  • 107.235.8 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 107.235.7 Boehringer Ingelheim Investigational Site
    Kansas City, Kansas, United States
  • 107.235.25 University of Louisville
    Louisville, Kentucky, United States
  • 107.235.16 Children's Hospital - Department of Rheumatology
    New Orleans, Louisiana, United States
  • 107.235.26 Deparment of Rheumatology
    Boston, Massachusetts, United States
  • 107.235.2 E15 Mayo Clinic
    Rochester, Minnesota, United States
  • 107.235.18 Washington University School of Medicine
    St. Louis, Missouri, United States
  • 107.235.9 Boehringer Ingelheim Investigational Site
    St. Louis, Missouri, United States
  • 107.235.31 Department of Pediatrics
    Omaha, Nebraska, United States
  • 107.235.35 Arthritis and Rheumatic Disease Center
    Livingston, New Jersey, United States
  • 107.235.24 The Children's Hospital of Buffalo
    Buffalo, New York, United States
  • 107.235.19 Columbia Presbyterian Medical Center
    New York, New York, United States
  • 107.235.22 Oklahoma Medical Research Foundation
    Oklahoma City, Oklahoma, United States
  • 107.235.33 Healthcare Research Consultants
    Tulsa, Oklahoma, United States
  • 107.235.32 Arthritis and Osteoporosis Center
    Duncansville, Pennsylvania, United States
  • 107.235.39 Division of Ambulatory Pediatrics
    Providence, Rhode Island, United States
  • 107.235.10 Texas Scottish Rite Hospital
    Dallas, Texas, United States
  • 107.235.1 University of Utah School of Medicine
    Salt Lake CIty, Utah, United States
  • 107.235.30 Children's Hospital
    Seattle, Washington, United States
  • 107.235.20 Medical College of Wisconsin
    Milwaukee, Wisconsin, United States
  • 107.235.61
    Cerqueira César, Brazil
  • 107.235.62
    Santa Cecília, Brazil
  • 107.235.60
    Sao Paulo, Brazil
  • 107.235.40
    México, D.F., Mexico
  • 107.235.71 Institute of Children and Adolescents Health
    Kharkov, Ukraine
  • 107.235.70 Children Clinical Hospital No. 1
    Kiev, Ukraine
  • 107.235.72 Institute of Pediatrics
    Kiev, Ukraine
  • 107.235.73 2nd Children Specialized Clinical Hospital "OHMADIT"
    Kiev, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2000 and a primary completion of Jun 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2002
First posted
May 3, 2002
Start
Dec 2000
Primary completionActual
Jun 2003
Last update
Nov 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00034853
First posted
May 3, 2002
Start date
Dec 2000
Primary completion
Jun 2003
Last update
Nov 1, 2013

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meloxicam · Naproxen

Start the discussion